Former Staff Scientist at the Fred Hutchinson Cancer Research Center (FHCRC) in Seattle, Washington, Dr. King has over 22 years of combined academic and private sector scientific research experience including utilizing cell culture and animal model systems to address a wide range of topics including cardiovascular disease, liver disease, thrombosis and cancer. In 1999, he obtained his Ph.D. in Genetics/Molecular Biology from the University of Hawaii at Manoa where he focused on the tumor suppressor and growth regulatory roles of gap junction proteins using cancer cell culture systems and mouse tumor models. Concurrently, he also studied the influence of retinoids and various carotenoids on normal and tumor cell growth/behavior, carcinogenesis and gene regulation. After graduation, he joined the FHCRC as a post-doctoral researcher where he investigated the combined and separate roles of gap junction proteins and cell cycle regulatory proteins on multi-organ tumorigenesis using several genetically-engineered mouse models. In 2004, he was appointed as a Staff Scientist at the FHCRC where he continued research until joining Hawaii Biotech, Inc. (Aiea, HI) as the Director of Cancer Chemoprevention from 2005-2006. Subsequently, he has served as Director of Biological Research (2006-2007) and Senior Director of Biological Research (2007-2009) at Cardax where as VP of Research he currently leads company scientific endeavors and has guided academic collaborations employing various animal models to evaluate drug efficacy in areas including atherosclerosis, thrombosis and liver disease. Dr. King also possesses an M.S. in Biology (Molecular Virology) from San Diego State University studying Rhadoviral transcription processes.

Recent Posts

Forward Looking Statements

This blog may contain certain forward-looking statements regarding our prospective performance and strategies within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, and are including this statement for purposes of said safe harbor provisions.
Forward-looking statements, which are based on certain assumptions and describe future plans, strategies, and expectations of our company, are generally identified by use of words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,” “project,” “seek,” “strive,” “try,” or future or conditional verbs such as “could,” “may,” “should,” “will,” “would,” or similar expressions. Our ability to predict results or the actual effects of our plans or strategies is inherently uncertain. Accordingly, actual results may differ materially from anticipated results. Some of the factors that could cause our actual results to differ from our expectations or beliefs include, without limitation, the risks discussed from time to time in our filings with the Securities and Exchange Commission.
Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this blog. Except as required by applicable law or regulation, we undertake no obligation to update these forward-looking statements to reflect events or circumstances that occur after the date on which such statements were made.

This Blog is official and sanctioned by Cardax, Inc. | See Disclaimer and Terms of Use

Get Cardax, Inc. Blog Post Alerts